Opus Genetics, Inc.
IRD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 6.8% | -34.1% | 1.6% | – |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | 99.6% | -109% | 100% | -80.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -564.2% | -308.5% | -155.8% | -233.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -566.9% | -257.5% | -187.5% | -816.7% |
| EPS Diluted | -0.25 | -0.12 | -0.24 | -1.11 |
| % Growth | -108.3% | 50% | 78.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |